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(57) ABSTRACT 
A device for collecting material from lung aerosols. The 
device functions by collecting aerosols from the lower airway 
separated from material in the by collecting air from the upper 
airway in a chamber that when full causes the remaining 
exhaled aerosols from the lungs to be captured by a filter. The 
filter collects sample of material from the separated lung 
aerosols. 
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LUNG AEROSOL COLLECTION DEVICE 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims priority from U.S. Provisional 
Application No: 61/140,292 filed Dec. 23, 2008, the entire 
contents of which are incorporated herein by reference. 
GOVERNMENT INTEREST 
This invention was made at Georgia Institute of Technol-
ogy and the Centers for Disease Control and Prevention. 
Therefore, the United States Government has certain rights in 
this invention. 
FIELD OF THE INVENTION 
2 
Accurate diagnosis of pneumonia is still a major problem 
and the field is innovating toward complex devices with mul-
tiple valves and chambers. There is an unmet need for a 
simple device for collecting a sufficient sample of lower 
airway material not contaminated by upper airway material 
for accurate detection clinical of pneumonia. Thus, there 
exists a need for a simple device and process for collection of 
lower respiratory air such as lung aerosols while minimizing 
or eliminating contaminating upper respiratory tract air from 
10 the sample. There further exists a need for a device that can 
collect materials such as pathogenic organisms from lower 
respiratory tract air without significant contamination from 
similar or identical organisms in the upper respiratory tract. 
15 SUMMARY OF THE INVENTION 
The invention relates to sampling exhaled air. More spe-
cifically the invention relates to collection of materials such 20 
as pathogens from alveolar aerosols or other lower respiratory 
aerosols to the exclusion of significant contamination by 
upper respiratory materials such as solid and liquid pathogens 
contained therein. 
A lower respiratory aerosol sample collection device is 
provided that is simple, inexpensive, and accurate for the 
collection of aerosols from the alveoli and bronchioles of the 
lung while excluding contaminating material from the upper 
airway. The inventive device functions without the need for 
complex valving, switching, or actual collection of air from 
the lower respiratory system. The inventive device does not 
require: electronic detection, collection, or measuring 
BACKGROUND OF THE INVENTION 
25 devices; chamber(s); resistance elements or shapes; or par-
ticular positioning. The inventive collection device also 
allows a sample oflower airway material from multiple exha-
lations to be obtained without the need for significant reset-Pneumonia, or an inflammation of the lungs, is a leading 
cause of morbidity and mortality worldwide. In 2002, there 
were 451 million lower respiratory infections reported to the 30 
World Health Organization. Worldwide, pneumonia accounts 
for nearly 30% of all deaths in children under the age of five, 
killing more children than AIDS, malaria, and measles com-
bined. In the United States, there were an estimated 1.4 mil-
lion hospitalizations and 59,000 deaths due to pneumonia in 
2002. Pneumonia can be caused by a variety of bacterial and 
viral pathogens, including streptococcus pneumoniae, myco-
plasma tuberculosis, influenza viruses, respiratory syncytial 
virus, parainfluenza, adenovirus, rhinovirus, human bocavi-
rus, influenza, Mycoplasma pneumoniae, hantavirus, and 
cytomegalovirus. 
ting of the device or collection of the air from a prior breath. 
An inventive device is optionally 50 percent or more effec-
tive at separating lower airway aerosols from upper airway 
material. More preferably, a device is 50-100 percent effec-
tive. Optionally, a device is 50, 60, 70, 80, or 90+ percent 
effective. Preferably, an inventive device is effective in a 
35 position with a shaft in a vertical orientation or 90 degrees 
either direction. Optionally, a shaft is in a lower position and 
the device will separate lower airway aerosols. 
An inventive lung aerosol separation and collection device 
includes a conduit into which a patient or other subject 
40 exhales or coughs via a first open end. A conduit optionally 
includes a narrowed section or Venturi channel whereby the 
exhaled fluid passes. The breath travels through the conduit 
which is connected to a shaft that preferably has higher flow 
resistance than a second open end. The conduit is also fluidly 
To treat this condition appropriately it is necessary to prop-
erly identify the pathogen in the lower airway. This can be 
done by checking for the presence of the pathogen, virus, 
bacteria or fungus, in the lung, i.e. alveoli and/or bronchioles. 
Obtaining a sample from the lung and confirming the etiology 
of pneumonia has proven difficult. For example, in the case of 
one of the leading causes of pneumonia, streptococcus pneu-
monia, as much as 70% of healthy people carry pneumococ-
cus in their upper respiratory system. This makes it difficult 
with the usual method of specimen collection, a sputum 
specimen, to confidently determine if a positive detection for 
S. Pneumoniae indicates carriage or the cause of pneumonia. 
A sputum specimen is collected after passing through the 
upper respiratory tract and mouth and is, therefore, contami-
nated with upper respiratory tract organisms. More invasive 
techniques including bronchial lavage, laparoscopic alveolar 
biopsy, or pleural tap do indicate presence of an organism in 
the lung but carry greater risk to the patient and are costly and 
painful. 
An easy to obtain sample of material from the diseased 
lung would greatly improve a physician's ability to diagnose 
and treat pneumonia. A sample of material from lung alveoli 
and bronchioles is also beneficial in various other situations 
such as determining the presence and concentration of alco-
hol in the blood stream and diagnosing disease processes such 
as lung cancer. 
45 connected to a chamber that serves to collect the upper airway 
air. As the upper airway air is expelled first during exhalation, 
the conduit fills to a predetermined volume. When full, the 
force of the full chamber allows the following lower airway 
air to be directed to the shaft and through the filter. It is 
50 preferred that the size of the chamber be less than 500 ml. The 
shaft is connected to a filter that lower airway air flows 
through. The filter functions to collect sample material from 
the lower airway air as it passes through. Target material such 
as bacteria, viruses, fungus, or other cellular or target mate-
55 rials are trapped in the filter while remaining lower airway air 
passes through the system. 
An inventive device optionally includes a trap to collect 
liquid material that may contaminate the filter or does not 
represent the aerosolized target material of interest. A trap is 
60 preferably positioned at a region of the conduit that is sub-
stantially opposite the shaft. 
An optional valve is present in the shaft or connected to the 
shaft whereby a force closes the valve prior to filling the 
chamber. The valve is preferably positioned in the shaft 
65 between the filter and the conduit. A valve is optionally a 
check valve, a quarter tum valve, diaphragm valve, globe 
valve, or other valve known in the art. Preferably, a valve is a 
US 8,821,409 B2 
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check valve. Several types of check valves are operable illus-
tratively including a ball, swing, clapper, stop, or a lift check 
valve. Most preferably, a check valve is a ball-check valve. 
4 
BRIEF DESCRIPTION OF THE DRAWINGS 
Optionally, a conduit includes a narrowed section or Ven-
turi channel whereby the exhaled fluid passes. An inventive 
device preferably functions by creating a negative flow in the 
shaft during the initial phase of exhalation where upper air-
way air is first expelled. This negative pressure can passively 
force the valve into a closed position by fluid passing through 10 
the narrow region of the conduit. 
FIG. 1 represents a preferred embodiment of the device; 
FIG. 2 represents two perspectives on the inventive conduit 
and shaft of a preferred embodiment of the inventive device; 
FIG. 3 represents an alternative embodiment of the inven-
tive device; 
FIG. 4 represents a schematic of an analyte detection 
embodiment of the inventive device; 
FIG. 5 represents a preferred embodiment of an inventive 
device; 
A preferred conduit has a curvilinear upper surface con-
tinuous with a lower surface that extends between a first end 
and a second end of the conduit. It is preferred that the shaft 
be connected to the conduit in at the upper surface. 
To direct proper positioning of the device in the oral cavity 
15 
FIG. 6 represents the oxygen levels in upper airway air or 
lower airway air as obtained by the inventive device. 
DETAILED DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
of a subject, one or more ridges are present on the conduit. 
Optionally, a first ridge is present in the upper surface and a 
second ridge is present in the lower surface. The ridges are 20 
optionally offset in distance from the first end. In one embodi-
ment, a ridge is from 5-35 mm from the first end of the 
conduit. Preferably the ridge is greater than 10 mm from the 
first end of the conduit. 
It is to be understood that the present invention is not 
limited to particular embodiments described, which may, of 
course, vary. It is also to be understood that the terminology 
used herein is for the purpose of describing particular 
embodiments only and is not intended to be limiting. 
The invention has utility for the collection of lower respi-
ratory tract air. The invention has further utility as a diagnostic 
An inventive device also optionally includes a trap. A trap 
is preferably located on the lower surface. It is preferred that 
the lower surface at the trap is below the lower surface at the 
first end and the lower surface at the narrow region during 
operation. This forms a depression in the device that serves to 
trap unwanted liquids from passing into the narrow region. 
A capacitive chamber is optionally present located 
between the filter and the conduit. 
In addition to an open first end, an inventive device option-
ally includes a mouthpiece located at the first end. The mouth-
piece optionally has a narrow cross sectional region and a 
wide cross sectional region and is connected to the first end at 
the wide region of the mouthpiece. 
An inventive process of collecting a sample from lung 
aerosols is provided. The inventive process includes separat-
ing lung aerosols from upper airway air by passing the lung 
aerosols through a filter not exposed to upper airway air and 
collecting a sample from the filter. The inventive process also 
optionally includes collecting sample from a second breath of 
a subject by passing lung aerosols from the second breath 
through the filter. Optionally, lung aerosols from multiple 
breaths is passed through the filter. Optionally, an inventive 
process includes collecting or sampling upper airway air that 
is separated from lower lung aerosols. 
A process of detecting or diagnosing a disease is also 
provided. A disease is optionally an infectious disease or a 
non-infectious disease illustratively cancer. The process 
includes separating lung aerosols from upper airway air and 
passing the lung aerosols through a filter not exposed to upper 
airway air. The process further includes collecting separated 
upper airway air and detecting the presence or absence of a 
pathogen in the lung aerosols and the upper airway air to 
diagnose the presence of a disease in the subject. 
A process of detecting the presence or concentration of an 
analyte is also provided. The process includes separating lung 
aerosols from upper airway air and exposing the lung aerosols 
to a detector not exposed to upper airway air and detecting the 
presence or absence of an analyte in the lung aerosols. The 
process optionally further includes exposing upper airway air 
to a second detector and detecting the presence or absence of 
an analyte in the upper airway air. 
25 aid for the detection and diagnosis of disease or abnormality. 
As the device is able to readily distinguish between the con-
tents of the lower respiratory tract and the upper respiratory 
tract, the device is operable for detecting the presence of 
alcohol in the blood independent of recent consumption and 
30 contamination by residuary alcohol in the mouth or upper 
digestive tract. 
The invention provides a segregated sampling of the aero-
solized material from the lower airway through the combina-
tion of a single flexible chamber and separate sampling appa-
35 ratus while minimizing the amount of contaminants from 
saliva and mucus collected from the oropharyngeal cavity. 
The device requires no power, active valves, or secondary 
apparatus. 
The invention provides for the diagnosis of infectious 
40 pneumonia that is simple and inexpensive. The device segre-
gates lower respiratory gas and aerosolized material from 
contaminants such as liquid from the mouth and gas or aero-
solized pathogens from the oral cavity. Illustratively, a filter 
traps the lung pathogens without a complicating second 
45 chamber. The outflow tract through the filter provides for low 
resistance and variable breath volumes. A simple fluid 
dynamics Venturi pressure system maintains segregation of 
gases during exhalation. A shaped mouthpiece effectively 
prevents large amounts of oral liquids from entering the 
50 device. An air-liquid trap uses gas diversion to further reduce 
liquid contamination. An elastic chamber of variable volume 
is optionally adjusted to the lung volume of individual 
patients such as a child with reduced lung volume or an adult 
with higher lung volume. Pathogens detectable or collectable 
55 by the inventive device optionally include, but are not limited 
to, Streptococcus Pneumonia, H. influenza, M. Tuberculosis, 
viruses, and fungi. Analytes detectable or collectible by the 
inventive device illustratively include: cells such as normal 
cells or abnormal cells illustratively including cancer cells; 
60 proteins illustratively including amylase; nucleic acids such 
as DNA or RNA; cytokines; chemokines; nitrogen oxide(s); 
carbon dioxide; acetone; alcohol including ethanol; glucose, 
or other sugars; and surfactant. An analyte is optionally a 
blood analyte. A blood analyte is preferably a molecule that is 
65 present in the bloodstream of a subject and is detectable in 
lung fluid. Illustratively, the amount of alcohol and acetone, 
as two examples of an analyte, in a sample of lung aerosols 
US 8,821,409 B2 
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will allow computation of total body fat as described in U.S. 
Pat. No. 4,114,422, the contents of which are incorporated 
herein by reference. 
The inventive device has any number of clinical uses in 
interrogating the respiratory system. Pathogens causing 
pneumonia of the lower airway are preferably sampled using 
the device. Exhaled ethanol from the bloodstream is option-
ally sampled more accurately using the device than is 
achieved using prior art devices. Inspired samples of asbestos 
6 
sectional areas of the ends 105, 107 to a narrowed internal 
region there between allows one to select the particle fraction 
such as an aerosol size for separation. 
A conduit 103 has a curvilinear upper surface continuous 
with a curvilinear lower surface. The curvilinear shapes of the 
upper surface and lower surface are optionally correlated or 
identical or are optionally independent such that the internal 
dimensions of the conduit 103 are not constant between the 
first end 105 and the second end 107. 
or coal are also optionally sampled to differentiate upper and 10 
lower airway origins. Cancer cells from the lower airway are 
differentiable from such cells present in upper airway origins. 
Oxygen in gas may need to be measured separately from 
oxygen in the liquid material in the upper airway. 
The conduit 103 is fluidly connected to a shaft 115. The 
shaft 115 preferably extends perpendicularly from the con-
duit 103. Optionally, the shaft 115 extends at an angle from 
the central axis of the conduit 103. The shaft 115 is preferably 
integral with the conduit 103. The shaft 115 is preferably 
made from the same material as the conduit 103 so as to form 
a single unified piece. The shaft 115 preferably bridges the 
As used herein the word "fluid" is defined as a non-solid 15 
substance. In a preferred embodiment a fluid is a gaseous 
substance. Illustratively a gas substance is air. Air is prefer-
ably air exhaled from a subject into the inventive device for 
separation and collection of material contained in the fluid. 
More preferably, air is coughed from a subject into the inven-
tive device for separation and collection of lower airway 
aerosols. 
As used herein the term "upper airway" air is defined as the 
air present in the oral cavity as the region external to the 
epiglottis. The volume of this air is dependent on the size of 
the subject. For a child the volume of upper airway air maybe 
as little as 50 ml. For a large adult the volume may be as much 
as 300 ml. Typically, an average adult will expel upper airway 
air in the first 100 to 150 ml of exhaled breath. 
As used herein the term "lower airway" air refers to air 
contained in the lungs, including bronchioles, alveolar sacs 
and alveoli when a subject has inhaled. The lower airway 
includes all anatomical structures internal to the epiglottis. 
conduit 103 to a sampling apparatus 117. 
In one embodiment, the shaft 115 is spatially offset relative 
to a central axis of the conduit 103. FIG. 1 depicts an elevated 
20 offset in a preferred embodiment. This offset directs the 
denser liquid material away from the shaft 115 and into a trap 
119 or other lower region of the conduit 103. The liquid 
material has a higher density and momentum than aerosolized 
particles and tends to travel in a straight line as fluid moves 
25 through the device 101. Thus, the conduit preferably is ori-
ented in line with the first end 105 while the shaft 115 pref-
erably extends at an angle from this line. Preferably, a shaft 
115 is located on the upper surface 108 of the conduit 103. 
The shaft 115 optionally incorporates a smaller opening or 
30 overlapping opening to further prevent liquids from entering 
as fluid passes through the device 101. A trap 119 is optionally 
located between the first end 105 and the shaft 115 on the 
conduit 103. The conduit 103 preferably forms a depressed 
As used herein the term "alveolar air" is used synony-
mously with lower airway air and includes air present in the 35 
lungs prior to exhaling including that from the alveoli, bron-
chioles, and other lung passages. 
shape with lower elevation with respect to the first end 105 
and the shaft 115 so as to form a trap 119 so that liquid 
contaminant from the upper airway is segregated from the 
aerosolized pathogens or other material present in the fluid 
from the lower airway. This prevents the liquid contaminant 
from being transported to the distal ends of the device 
improving separation of alveolar material. 
As used herein the term "lung aerosols" means any mate-
rial aerosolized in fluid from the lower airway. 
It is appreciated that the inventive device operates without 40 
active or electronically controlled valves, colorimetric or 
other specific indicators, pistons, multiple collection or diver-
sion chambers, condenser tubes, heating or cooling mecha-
nisms. In a preferred embodiment an inventive device 
samples material in lung aerosols without collection of the air 45 
itself or sampling of the lung aerosols. 
At the conduit second end 107 is preferably a chamber 125. 
Chamber 125 has an entrance opening that preferably pro-
vides lower flow resistance than the entrance opening of the 
first end 105 of the conduit 103. More preferably, the chamber 
entrance opening is of the same cross sectional area as the 
fourth area 121 of the conduit 103. The differences in flow 
Referring to FIG. 1, an inventive device 101 includes a 
conduit 103 with a first end 105 and a second end 107. Fluid 
104 passes through said conduit 103. The conduit is prefer-
ably used in a substantially horizontal orientation with 
respect to the elevation of the first end 105 and the second end 
107. The conduit is optionally made from polymeric material, 
metal, glass, and the like. 
In the pictured embodiment of FIG. 1, the conduit 103 is 
substantially linear so as to form a cylindrical cross sectional 
area. It is appreciated that the cross sectional area of the 
internal space of the conduit 103 need not be circular. The 
cross sectional area is optionally oblong, square, rectangular, 
triangular, irregular, or any other shape. The conduit 103 is 
optionally non-linear from the first end 105 to the second end 
107. Preferably, the fluid path from the first end 105 through 
the device is not linear and has one or more bends so that 
particles with more density will impinge on the wall of the 
conduit lumen. The bend(s) causes particles with greater 
mass and momentum to hit the wall of the conduit 103, 
whereas lighter aerosolized particles will more easily pass 
therethrough. It is appreciated that relative sizing of the cross 
resistance allows fluid flow to pass into the chamber 125 
before the shaft 115 as flow will follow the path of least 
resistance. Fluid will then pass into the chamber 125 filling it. 
50 Preferably, the chamber 125 is made from a flexible material 
so that the chamber 125 will expand from the presence of 
incoming fluid to a maximum internal volume. The maximum 
internal volume is defined by the internal area of the chamber 
125 and the elasticity of the chamber material. Preferably, the 
55 chamber is made from material with low elasticity. A chamber 
125 is preferably elastic to provide shock-absorbing compli-
ance during coughing. Optionally, the chamber 125 is made 
from material with substantially no elasticity. The chamber is 
optionally made from natural or synthetic materials illustra-
60 tively including latex, rubber, polymeric material, glass, 
metal, and the like. 
In an embodiment with a flexible chamber 125, the volume 
of chamber 125 will increase to a predetermined amount with 
breath from the upper airway. After inflation of chamber 125, 
65 resistance to further inflation occurs proving sufficient resis-
tance such that additional exhaled breath from the lower 
airway will then pass into the shaft 115. In one embodiment, 
US 8,821,409 B2 
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the aerosol content is filtered for pathogen directly. In another 
embodiment, the entire lower airway breath is collected in a 
second chamber. 
The chamber 125 is preferably a flexible material that can 
be collapsed by physical force or expanded by capture of 
upper respiratory air. Optionally, a chamber 125 is a solid 
material such as glass, metal, rigid polymers and the like. 
The average normal (tidal) exhalation in a healthy adult is 
approximately 500 ml. Of this 500 ml, the initial 150 ml of 
exhaled gas is from the upper airway including the trachea, 10 
and oropharyngeal space. This portion of gas is commonly 
referred to as the "dead space" since it does not contribute to 
oxygen refreshment to the lungs. The latter 350+ ml of 
exhaled gas comes from the lower respiratory airway and 
alveoli. Thus, chamber 125 preferably expands to 150 ml and 15 
then provides resistance to further inflation. The lower airway 
breath of 350 ml is then diverted into the shaft 115. By 
separating the initial 150 ml from the 500 ml sample, it is 
possible to isolate the contaminating bacteria in the first 150 
ml from the true pneumonia pathogens present the alveolar 20 
space contained in the subsequently exhaled 350 ml of air. 
A chamber 125 is preferably of sufficient internal volume 
to capture all upper respiratory air. Preferably, a chamber 125 
has an internal volume of less than 300 ml. Optionally, a 
chamber has a volume between 25 ml and 300 ml. More 25 
preferably, a chamber has an internal volume between 50 and 
150 ml. Most preferably, a chamber has an internal volume of 
100-150 ml. 
8 
Fluid is optionally exhaled fluid from a subject, fluid 
exhaled during a cough, or a rapid forced exhalation. 
In one embodiment a filter is present in a cartridge that 
attaches to a shaft 115. Optionally, the filter cartridge 127 
attaches to a shaft 115 by way of a press fit. Optionally, a filter 
cartridge 127 attaches to a shaft 115 by a screw fit, clamp, 
intermediate connector, or other type of fitting known in the 
art. 
An inventive device optionally includes a valve 129 
between the sampling apparatus 117 and the conduit 103. A 
valve 129 is preferably housed within a shaft 115. It is appre-
ciated that a valve is optionally placed between the shaft 115 
and the conduit 103, or between the shaft 115 and the sam-
pling apparatus 117, or filter cartridge 127. A valve preferably 
will close the internal area of the shaft 115 reducing or elimi-
nating fluid flow from the conduit 103 to the shaft 115. A 
valve is optionally a check valve, a ball valve, a diaphragm 
valve, a globe valve, and the like. Preferably, a valve is a check 
valve. Types of check valves illustratively include a ball, 
diaphragm, swing, clapper, stop-check, lift-check, and the 
like. In a preferred embodiment a valve is a ball-check valve. 
A valve is preferably a passive valve such that user input other 
than exhaling or coughing is not required for proper operation 
of the device. 
An inventive device optionally includes a mouthpiece 137 
located at the first end 105. A mouthpiece 137 is optionally a 
tapered shape whereby the taper is preferably not constant. 
The tapered shape produces a narrow region 143 and a wide 
region 145. The mouthpiece 137 preferably extends posterior The chamber 125 is optionally adjusted or replaced with a 
different size chamber to collect different volumes depending 
on the size of the patient. For instance, a child may require the 
chamber to collect a volume of only 50 ml, while a large adult 
may require collection of 300 ml. 
A shaft 115 preferably terminates in or includes a sampling 
apparatus 117. A sampling apparatus 117 is optionally a 
detector or a filter. In a preferred embodiment a sampling 
apparatus 117 is a filter. A filter is preferably of any suitable 
material to allow gaseous fluid to pass through the filter while 
trapping materials contained in the fluid such as pathogens 
including virus particles, bacteria, yeast, fungus, and the like. 
30 to the teeth of a subject during exhalation. This extension 
prevents saliva and other mouth contents from entering the 
device. The extension also reduces the amount of upper air-
way material entering the collection device. Preferably, the 
mouthpiece 137 has an opening entrance at the proximal end 
35 which is located posterior to the teeth of a subject during 
exhalation. More preferably, the entrance is more than 10 mm 
posterior to the teeth. The mouthpiece optionally a round, 
oval, square, or rectangular opening. In a preferred embodi-
ment the proximal opening of the mouthpiece is smaller in 
40 cross sectional area than the exit to the conduit 103. This 
A filter optionally traps environmental contaminants such as 
asbestos, fiberglass, pesticides and the like. A filter is option-
ally made from paper, gelatin, polymers, glass, or other mate-
rial. The material is preferably operable for collecting target 
material. Optionally, a filter is sized so as to collect some 45 
targeted materials while letting others pass thorough. Illus-
tratively, a filter is used to trap bacteria. Optionally, bacteria is 
mouthpiece configuration prevents unwanted upper airway 
and oral cavity material from entering the collection device 
during use. By positioning the entrance of the device appro-
priately, the liquid saliva and sputum does not enter the device 
in large amounts. Mouthpieces of different size entrance 
openings are optionally utilized for patients of different size 
for collecting coughs versus deep breath exhalation. A one-
way valve is optionally included in the mouthpiece 137 to 
prevent backflow. 
S. pneumonia. Optionally, a filter will trap virus particles. 
Optionally, a filter is made of reactive material that will inter-
act with a target molecule or pathogen thereby trapping the 50 
molecule or pathogen in the filter while selectively allowing 
non-targets to pass through the filter. In one embodiment a 
filter is less than 100% effective at trapping a target. Filter 
materials suitable for use with the inventive device are known 
Referring to FIG. 2 maintaining like numerals, a shaft 215 
is preferably located at the narrowed region ("Venturi chan-
nel") 223 of the conduit 203. Without being limited to one 
operational mechanism, the increased fluid flow rate through 
the Venturi channel 223 causes a negative pressure within the 
in the art and are obtained from sources known in the art, 
illustratively, 3M Corp. (St. Paul, Minn.). In a preferred 
embodiment the VBMax filters from A-M Systems, Inc. 
(Carlsborg, Wash.) are used. 
A filter will preferably allow the velocity and volume of 
lower airway fluid associated with a cough to readily pass 
though the filter without significant resistance so material 
from the coughed lower airway fluid can be readily collected 
on the filter. Without significant resistance is preferably no 
more resistance than necessary to trap desired material on or 
in the filter. It is preferred that the device provide minimal 
resistance to lower airway fluid passing through the shaft to 
contact a detection apparatus. 
55 shaft 215. The negative pressure brings the valve 229 into a 
closed position, thus, preventing fluid from entering the shaft 
prior to full inflation of the chamber 225. It is appreciated that 
this negative pressure is present independent of the presence 
of a valve in the shaft such that fluid is prevented from enter-
60 ing the shaft prior to chamber inflation simply due to the 
increased fluid flow rate in the Venturi channel 223 of the 
conduit 203. As such, the valve is optional, yet preferred. 
An inventive conduit optionally has a first cross sectional 
area 209 defined as the internal cross sectional area at the first 
65 end 205. A cross sectional second area 211 is the internal 
cross sectional area at a point some distance toward the sec-
ond end 207. Preferably, the first cross sectional area 209 is 
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larger than the second cross sectional area 211. Optionally, 
the first cross sectional area 209 is the same as the second 
cross sectional area 211. It is appreciated that a first cross 
sectional area 209 is optionally smaller than a second cross 
sectional area 211. A third cross sectional area 213 is defined 
as an internal cross sectional area at a location in the conduit 
203 intermediate of the first cross sectional area 209 and the 
second cross sectional area 211. 
10 
shaft 315 or is a pliable section that will expand in the pres-
ence of a rapid increase in pressure/volume due to a cough. 
The patient may be asked to inhale deeply and cough to expel 
more contents from the alveoli. The device can accommodate 
high pressures generated by such a cough and still segregate 
the lower airway material. 
As illustrated in FIG. 4, in one embodiment a sampling 
apparatus is one or more detectors 441. A detector 441 is 
optionally positioned in a shaft 415 so that lower airway/lung A preferred embodiment includes a conduit with a fourth 
area 221. Preferably, the second area 211 is smaller than the 
third area 213 and the fourth area 221. This forces the fluid 
into an area of lower cross sectional area forming a Venturi 
channel 223. The Venturi channel is a narrowed flow section 
that causes higher fluid velocity and consequently, lower 
dynamic pressure through the flow section. This creates a 
negative pressure in the shaft 215 during movement of upper 
airway fluid through the conduit 203. The Venturi channel 
223 will prevent fluid motion toward the filter 217 during the 
first part of exhalation when upper airway fluid is passing 
thorough the device. 
10 aerosols is exposed to a detector during an exhalation of a 
subject. Optionally, a second detector is present within the 
conduit 403. The second detector is preferably located dis-
tally from the shaft within the conduit 403 or within the 
chamber 425 so that it is not exposed to lower airway air and 
15 is used to detect the presence of a target in the upper airway. 
A detector is optionally operable to detect the presence or 
absence of a bacteria, virus, fungus, antibody, protein, or 
chemical such as carbon dioxide, carbon monoxide, nitric 
oxide, alcohol and the like. In one embodiment a detector is 
A conduit 203 preferably includes one or more positions 
206 defining a distance from the teeth of a subject to the first 
end of the device when the device is used in the mouth of a 
subject. A position 206 is optionally an identifiable region on 
the conduit that a user or administrator locates to associate the 
teeth of a user for proper positioning of the device. A position 
206 is optionally greater than 10 millimeters from the first 
end. Optionally, a position 206 is 10 to 80 millimeters from 
the first end. In a most preferred embodiment, a position 206 
20 capable of detecting the presence of alcohol in the lower or 
upper airway of a subject. A detector is optionally a surface, 
a labyrinth, a trap, sticky substance, warmed or cold surface, 
metal, or electrical, chemical or mechanical sensor. A sensor 
or other detector is illustratively operable to detect a molecule 
25 or pathogen, either by color, optical, or electronic or other 
chemical means. 
is from 20 to 30 millimeters from the first end. A position 206 30 
is optionally one or more locations such as a line, color 
change, ridge, channel, depression, joint, or other visual, 
tactile, auditory, or measurably identifiable location. 
In a preferred embodiment a position is defined by one or 
more ridges. A ridge is preferably dimensioned so that a 35 
subject's teeth will engage the ridge during exhalation. A first 
ridge 231 is preferably located on the upper surface 208 of the 
conduit 203. A second ridge 233 is located on the lower 
surface 210 of the conduit 203. The ridges optionally define a 
region of increased outer circumference. Located toward the 40 
first end 205 on the conduit 203 is optionally a channel 235 
that acts as a position. During operation a user fits his teeth 
within the channel at the point of the ridges. This helps define 
the location of the device in the oral cavity. Preferably, the 
ridges 231, 233 are between 5 and 80 mm from the first end 45 
205. More preferably, the ridges 231,233 are greater than 10 
mm from the first end 205. Most preferably, the ridges 231, 
233 are 25 mm from the first end 205. Optionally, the first 
ridge 231 is positioned further from the first end 205 than the 
second ridge 233. This offset orientation comfortably accom- 50 
modates a natural overbite of a user. Optionally, a first ridge 
231 is positioned nearer to the first end 205 than the second 
ridge 233. 
A trap 219 is positioned between the narrow region 223 and 
the ridges 231, 233. This trap 219 defines a region in the lower 55 
surface 210 of the conduit 203 below the lower surface at the 
One or more parts of an inventive device are optionally 
reusable. Illustratively, a conduit is sterilizable such as by 
autoclaving for reuse to reduce possibility of contamination 
from a prior use. Optionally, the conduit and shaft are reus-
able. Optionally, the entire device is reusable. 
While the inventive device is preferably used with the first 
end positioned posterior to the front teeth, it is appreciated 
that the device is similarly functional positioned near, at, or in 
front of the teeth. 
A process is provided for detecting the presence or absence 
of material from the lower airway as exhaled, preferably by 
coughing, by a subject to the exclusion of material from the 
upper airway. An inventive process illustratively includes 
separating lung aerosols from upper airway air using an 
inventive device; contacting the lung aerosols with one or 
more sampling apparatuses, optionally excluding upper air-
way air from contacting a sampling apparatus, and optionally 
collecting a sample on the sampling apparatus. 
An inventive process optionally includes separating lung 
aerosols from a second breath. A breath as used herein is a 
single round of respiration including inhaling and exhaling. 
Exhaling preferably includes one or more coughs. Collecting 
material from a cough or multiple coughs is most preferred. 
The inventive device is operable for separating lung aerosols 
from as many breaths as is desired to improve detection of 
target material. As the exit of the shaft preferably freely 
dispels air, as much air as is desired is optionally passed 
through the filter by way of collection of several successive 
exhalations. The device preferably does not require collection 
of the lower airway air for reuse or sampling. The inventive 
process preferably collects aerosols from two exhaled 
breaths. Optionally, the inventive process includes collection 
of multiple breaths. Multiple breaths is optionally two, three, 
first end 205 and below the lower surface at the narrow region 
223. This configuration collects unwanted liquid as the fluid 
passes from the first end toward the narrow region due to the 
curvilinear shape of the conduit 203. 
Referring to FIG. 3, an inventive collection device option-
ally includes a second chamber such as a capacitive chamber 
339 located between the conduit 303 and the shaft 315. A 
capacitive chamber 339 operates to absorb the high pressure/ 
volume of a cough that can be slowly bled out to the chamber 
325 without allowing upper airway air to enter the filter. A 
capacitive chamber 339 is optionally an enlargement of the 
60 four, five, six, seven, eight, nine, ten, or more breaths. It is 
appreciated that the device is not limited to any number of 
breaths. 
An inventive process optionally includes collecting the 
upper airway fluid. Upper airway aerosols or liquid are 
65 optionally collected by removing the material trapped in the 
chamber or in the conduit following an exhaled breath. A 
chamber optionally has a valve or other collection opening to 
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facilitate collection of upper airway material. The upper air-
way aerosol is optionally sampled. A second filter, detector, 
or sensor is optionally present within or at an exit portion of 
a chamber, in the conduit, or in the chamber for collection of 
the aerosols. A one-way valve is optionally present in the 
conduit preferably positioned toward the second end such that 
upper airway air may freely flow into the chamber until maxi-
mal expansion. After the exhalation is complete a user option-
ally collapses a chamber optionally forcing collected upper 
airway air through a second sampling apparatus capturing, 10 
sensing, or detecting upper airway material without forcing 
this material back into the conduit preventing possible con-
tamination of the filter in the shaft. 
12 
Human subjects (patients) are sampled as approved by 
Georgia Institute of Technology Institution Review Board as 
IRB Protocol H08353. Patients are asked to expel a deep 
cough into the device and continue exhaling residual air in the 
lungs. Coughing and sneezing aerosolize a greater number of 
lower lung pathogens as compared to exhalation alone. 
Example 2 
Oxygen Separation Test: Oxygen absorption by blood 
occurs only in the lower airway (alveoli), and not in the upper 
airway (mouth, trachea). Thus the oxygen level in the lower 
airway is expected to be less than that of the upper airway. 
15 
Ambient atmosphere contains approximately 21% oxygen, 
while expired air is about 16.5% oxygen. The oxygen content 
from the upper airway chamber is tested and compared with 
a sample from a collection chamber located on a shaft. The 
percentage of oxygen in each sample is measured with an 
Detection of material from either the upper airway or the 
lower airway is optionally by polymerase chain reaction 
(PCR), real-time PCR, reverse-transcription PCR, enzyme 
linked immunosorbant assay (ELISA), mass spectrometry, 
liquid chromatography, Southern blotting, western blotting, 
northern blotting, enzymatic assay, culturing, cell infection, 
other assays known in the art, or combinations thereof to 
selectively amplify or identify material from either lower 
airway aerosols or upper airway liquid or aerosols. The afore-
mentioned detection or identification methods are generally 
known to those of skill in the art and are described in detail in 
methodology treatises such as Molecular Cloning: A Labo- 25 
ratory Manual, 2nd ed., vol. 1-3, ed. Sambrook et al., Cold 
Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 
1989; and Current Protocols in Molecular Biology, ed. 
Ausubel et al., Greene Publishing and Wiley-Interscience, 
New York, 1992 (with periodic updates). Immunological 30 
methods (e.g., preparation of antigen-specific antibodies, 
immunoprecipitation, and immunoblotting) are described, 
e.g., in Current Protocols in Immunology, ed. Coligan et al., 
John Wiley& Sons, New York, 1991; and Methods oflmmu-
nological Analysis, ed. Masseyeff et al., John Wiley & Sons, 35 
New York, 1992; among others. The contents of each of which 
are incorporated herein by reference. 
20 oxygen meter (Teledyne Analytical Instruments, Model# GB 
300). The experiment is repeated using the device ofExample 
1 ten times with statistical significance defined at the p<0.05 
level. 
A process of diagnosing a disease is presented including 
separating lung aerosols from upper airway aerosols by pass-
ing the lung aerosols through a filter and excluding upper 40 
airway aerosols; collecting the upper airway material; and 
detecting the presence or absence of a pathogen, disease cell, 
protein, or other target in the lung aerosols or upper airway. A 
disease is optionally diagnosed by detecting a target. Illustra-
tively, a disease is cancer. A user optionally diagnoses the 45 
presence of cancer cells by location to either the lower airway 
or the upper airway. 
A process for detecting an analyte in the blood stream of a 
subject is provided. The inventive process includes separating 
lung aerosols from upper airway aerosols by a subject exhal- 50 
ing; and detecting the presence or absence of an analyte on a 
filter or detector present in lower airway aerosols. 
Various aspects of the present invention are illustrated by 
the following non-limiting examples. The examples are for 
illustrative purposes and are not a limitation on any practice of 55 
the present invention. It will be understood that variations and 
modifications can be made without departing from the spirit 
and scope of the invention. 
As depicted in FIG. 6, the average percentage of oxygen in 
lower airway sample as passed through the filter is 15.9%, 
whereas the average upper airway sample is 18.4%. The 
average percentage of the room air oxygen as breathed by the 
patients is 20.9%. The lower airway sample is statistically 
lower than the upper airway sample or the room air with a 
p-value of <0.0001, n=l 0. These data indicate that the inven-
tive device successfully separates lower airway air from 
upper airway air. 
A second test variation is performed to assess the function 
of the ball valve. The Oxygen Separation Test is performed 
without the ball valve to determine the effect of the ball valve 
on the separation oflower airway samples from upper airway 
oxygen content. In the absence of the ball portion of the 
ball-check valve, the average percentage of oxygen in the 
lower airway sample is 16.9% compared to the upper airway 
sample of 18.9% (p<0.0001 ). The average percentage of oxy-
gen in the lower airway sample with the ball valve is 15.9% 
and without the ball valve is 16.9% (p<0.0001). 
Example 3 
Detection of blood ethanol in lower-respiratory air. 
Ingested ethanol appears 20 minutes later in the blood stream 
and becomes volatile in the alveolar space, not in the upper 
airway. Two 0.02% breath alcohol testers (Advanced Safety 
Devices) are connected to the inventive device. One detector 
samples lower airway air and is connected to the shaft. The 
second detector is positioned within the chamber. Participants 
drink 50 proof alcohol, 60 ml for females and 80 ml for males. 
Participants then rinse the mouth with water but are not 
allowed to swallow the water. After 20 minutes, the partici-
pant drinks an 8 oz glass of water and then deep coughs and 
exhales residual air into the inventive device as described in 
Example 1. The color changing crystals are allowed to 
develop for 2 minutes. The paired breath alcohol testers are 
Example 1 60 photographed and resulting color analyzed with photo editing 
software and the quantitative saturation and blue levels are 
measured. A breath separation and collection device is depicted in 
FIG. 5. The device includes a single piece conduit and shaft 
substantially as depicted in FIG. 2. A ball-check valve is 
present in the shaft. A filter is connected to the shaft and 65 
housed in a filter cartridge. A flexible chamber is attached to 
the second end of the conduit. 
As a control, the volume of lower airway aerosols is 
directed into the chamber and thus, through the second detec-
tor. The participant coughs and exhales residual air into the 
device. After 2 minutes, the breath alcohol tester with 
restricted volume is photographed and analyzed. 
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In all cases, the lower airway samples change color, 
whereas the upper airway samples do not. The differences 
results in p-values as follows: saturation-p=0.0015; and 
blue-p=0.0019. As a control, the chamber volume is sepa-
rately tested to assure that this volume was enough to convert 
the colorimetric crystals. Since these three values of the alco-
hol crystals are significantly different the device successfully 
samples the volatiles generated in the lower airway separately 
from the upper airway. 
Example 4 
Negative pressure created by a Venturi channel: The filter 
10 
14 
The inventive device functions with dramatic angle of posi-
tioning relative to the plane of the face. When the device is 
placed 45 degrees from the perpendicular to the plane of the 
face in any direction no liquid enters the device, as long as the 
mouthpiece is positioned correctly with the lips at the ridge on 
the mouthpiece and the opening behind the teeth. 
Example 6 
of the device of Example 1 is replaced with a thin plastic bag 
filled with 50 ml of air and the chamber is removed. The 15 
Phlegm Exclusion Test: A 2.5 ml volume of viscous solid 
jelly is used as a surrogate for phlegm in the oral cavity. The 
participant coughs into the device with proper and improper 
mouthpiece placement. The amount of jelly on the filter of the 
device of Example 1 is measured and recorded. This amount 
is compared to the control of expectorating the jelly sample 
directly into a sputum cup. When the device is correctly 
positioned no phlegm attaches to the device filter. In the one 
trial where jelly was observed on the filter the amount was less 
direction of flow through the Venturi is quantified by the time 
required to deflate a fixed 50 ml thin bag. With every exhala-
tion, the 50 ml bag attached to the filter tube fully deflated 
over an average of 1.25+/-0.25 s. Table 1 shows the results of 
the Venturi test illustrating deflation of the filter bag. Thus, the 
Venturi creates a negative pressure in the shaft. The results 
demonstrate that the device prevents the initial upper airway 
gas from passing through the collection chamber during deep 
coughing. 
TABLE 1 
n Time (s)* 
1.47 
2 0.93 
1.6 
4 1.07 
1.2 
AVERAGE: 1.25 +/- 0.25 
*Time to deflate bag over filter while blowing through device. 
Example 5 
Proper positioning of the device in the mouth: The device 
20 than 1 % the starting volume. 
Example 7 
Collection ofliquid in the trap: The device of Example 1 is 
25 tested whereby the volume of material contained in the trap 
during deep coughing is measured after successively larger 
oral volumes of 1, 2, 3, and 4 ml of water is present in the 
mouth prior to cough. The experiment is repeated three times. 
With a starting oral volume of 1 ml ofliquid, 0.5 ml ofliquid 
30 is dispose in the liquid trap after the deep cough. The results 
of the Trap Test are shown in Table 4. The liquid trap effec-
tively captures 0.5 to 0.8 ml of oral liquids from reaching the 
outlets of the device during deep coughing. 
35 TABLE4 
Oral Volume (ml) Volume Collected in Trap (ml) 
of Example 1 is tested in the correct position with the teeth in 40 
the channel at the base of the ridge and the first end extending 
1.0 
2.0 
3.0 
4.0 
0.5 
0.6 
0.6 
0.8 
25 mm proximal to the teeth for the correct position and 
compared with an incorrect position with the opening at the 
first end of the device less than 10 mm proximal to the teeth. 
After deep coughing into the device, the amount ofliquid that 45 
enters the device is measured and recorded for an initial oral 
volume of volume of 5, 7.5, 10, and 15 ml of water. The 
experiment is repeated for a total of three measurements for 
each initial volume of water. 
Example 8 
The device of Example 1 is used with a VB Max filter. A 
Bacterial Filtration Efficiency Test and a Viral Filtration Effi-
ciency Test are performed. Both test procedures are adapted 
from ASTM F2101. The bacterial filtration efficiency test 
When the mouthpiece is correctly positioned, no water 
enters the device, even when the amount of water starting in 
the mouth is increased to 15 ml (Table 2). A significant 
amount of water enters the device with incorrect device posi-
tioning. 
50 uses the challenge organism Staphylococcus aureus (proce-
dure number STP0009 Rev 02). The viral filtration efficiency 
test uses bacteriophage cjJXl 74 as the challenge organism. 
TABLE2 
Ending Volume in device (ml)l 
Initial Oral 
Volume (ml)t 
7.5 
10 
15 
Correctly Positioned 
Mouthpiece 
0 
0 
0 
0 
*Statistically significant 
tvolume of liquid expelled into device 
Incorrectly Positioned 
Mouthpiece 
0.8 
3.7 
5.5 
7.5 
p-value 
0.0075* 
0.0142* 
0.0062* 
0.0020* 
The average Bacteria Filtration Efficiency is found to be 
99.99977%. For the Viral Filtration Efficiency, the average 
55 filtration efficiency is 99.9975% with a mean particle size of 
2.Sµm. 
60 
65 
Various modifications of the present invention, in addition 
to those shown and described herein, will be apparent to those 
skilled in the art of the above description. Such modifications 
are also intended to fall within the scope of the appended 
claims. 
Patents and publications mentioned in the specification are 
indicative of the levels of those skilled in the art to which the 
invention pertains. These patents and publications are incor-
porated herein by reference to the same extent as if each 
individual application or publication was specifically and 
individually incorporated herein by reference. 
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The foregoing description is illustrative of particular 
embodiments of the invention, but is not meant to be a limi-
tation upon the practice thereof. The following claims, 
including all equivalents thereof, are intended to define the 
scope of the invention. 
The invention claimed is: 
1. A process of sampling aerosolized lung material com-
prising: providing a collection device comprising a conduit 
having a first open end and a second end, said conduit con-
nected to a filter; separating upper airway fluid from aero-
solized lung material lower airway fluid by inserting said first 
open end of said collection device a distance posterior to at 
least one tooth of a subject, wherein the first open end is 
located in the oral cavity of the subject, and sampling the 
aerosolized lung material by passing the aerosolized lung 
material through said conduit, while the first open end is 
located in the oral cavity of the subject, said aerosolized lung 
material lower airway fluid traversing said filter to trap aero-
solized material in said filter. 
2. The process of claim 1 wherein said distance is 5 milli-
meters or more posterior to at least one tooth of the subject. 
3. The process of claim 1 wherein said distance is between 
5 and 80 millimeters posterior to at least one tooth of the 
subject. 
4. The process of claim 1 wherein said distance is from 20 
to 30 millimeters posterior to at least one tooth of the subject. 
16 
at least a portion of said shaft between said conduit and said 
filter. 
7. The process of claim 1 wherein said device further 
comprises a chamber fluidly connected to said conduit at said 
second end. 
8. A process of discriminatorily sampling lower airway 
~aterial cm?prisi~g: providing a collection device compris-
mg a condmt havmg a first open end and a second end, said 
c?nduit cm:mected to a sampling apparatus; separating upper 
10 
airway flmd from lower airway aerosolized material by 
inserting said first open end of said collection device a dis-
tance posterior to at least one tooth of a subject, wherein the 
first open end is located in the oral cavity of the subject; and 
contacting said lower airway aerosolized material with said 
sampling apparatus to sample the aerosolized lung material 
15 by passing the aerosolized lung material through said conduit, 
while the first open end is located in the oral cavity of the 
subject. 
20 
25 
9. The process of claim 8 wherein said sampling apparatus 
is a filter or a detector. 
10. The process of claim 8 wherein said distance is greater 
than 5 millimeters posterior to at least one tooth of the subject. 
11. The process of claim 8 wherein said distance is between 
5 and 80 millimeters posterior to at least one tooth of the 
subject. 
5. The process of claim 1 wherein said device further 
comprises an identifiable position on said conduit between 
said first open end and said second end, said position defining 30 
said distance during collection of aerosolized material from a 
lung. 
12. The process of claim 8 wherein said distance is between 
20 and 30 millimeters posterior to at least one tooth of the 
subject. 
13. The process of claim 8 wherein said material is an 
analyte. 
14. The process of claim 13 further comprising: 
detecting the presence or absence of said analyte interact-
ing with said sampling apparatus. 6. The process of claim 1 wherein said device further 
comprises a shaft fluidly connected to said conduit; 
* * * * * 
